BioCentury
ARTICLE | Clinical News

Adamas' ADS-5102 improves levodopa-induced dyskinesia

June 19, 2013 12:47 AM UTC

Adamas Pharmaceuticals Inc. (Emeryville, Calif.) said once-daily doses of oral ADS-5102 improved levodopa-induced dyskinesia in the Phase II/III EASED trial in patients with Parkinson's disease (PD). Specifically, once-daily 340 and 420 mg doses of oral ADS-5102 met the primary endpoint of improving levodopa-induced dyskinesia as measured by the mean change in Unified Dyskinesia Rating Scale (UDysRS) total score from baseline to week eight vs. placebo (p=0.005 and p=0.013, respectively). The once-daily 260 mg dose of ADS-5102 led to a non-significant improvement on the endpoint (p=0.159). The double-blind, U.S. trial enrolled 83 patients with PD. Data were presented at the Parkinson's Disease and Movement Disorders meeting in Sydney. ...